Navigation Links
PharmAthene Reports Third Quarter 2011 Financial and Operating Results
Date:11/9/2011

rsuant to an opinion issued September 22, 2011 from the Delaware Court of Chancery, PharmAthene is entitled to 50% of the net profits over 10 years from all sales of SIGA Technologies' ST-246, a novel smallpox antiviral agent being developed by SIGA for the treatment and prevention of morbidity and mortality associated with exposure to the causative agent of smallpox, and related products, once SIGA receives the first $40 million in net profits from sales of ST-246.  For more information about PharmAthene, please visit www.PharmAthene.com.

Statement on Cautionary Factors Except for the historical information presented herein, matters discussed may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "potential"; "believe"; "anticipate"; "intend"; "plan"; "expect"; "estimate"; "could"; "may"; "should"; "will"; "project"; "potential"; or similar statements are forward-looking statements. PharmAthene disclaims any intent or obligation to update these forward-looking statements other than as required by law. Risks and uncertainties include risk associated with the reliability of the results of the studies relating to human safety and possible adverse effects resulting from the administration of the Company's product candidates, unexpected funding delays and/or reductions or elimination of U.S. government funding for one or more of the Company's development programs, the award of government contracts to our competitors, unforeseen safety issues, challenges related to the development, scale-up, technology transfer, and/or process validation of manu
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. PharmAthene Progresses Second Generation rPA Anthrax Vaccine
2. PharmAthene Appoints Brian A. Markison to the Companys Board of Directors
3. PharmAthene Achieves Significant Progress in SparVax™ Anthrax Vaccine Program
4. Department of Defense Awards $5.7 Million Contract to PharmAthene for Nerve Agent Medical Countermeasure Program
5. PharmAthene Selected for Inclusion in the Russell Global Index and Russell 3000 Index
6. PharmAthene Achieves Anthrax Vaccine Program Milestone and Successfully Completes Technology Transfer
7. PharmAthene Completes $6.5 Million Registered Direct Offering
8. PharmAthene Reports First Quarter 2011 Financial and Operating Results
9. PharmAthene to Host Year-End 2010 Earnings Conference Call and Webcast on Monday, March 28, 2011
10. PharmAthene Strengthens Scientific Leadership and Program Management for Future Growth
11. PharmAthene Receives FDA Clearance to Reinitiate Clinical Testing of Valortim®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... Port Washington, NY (PRWEB) May 22, 2013 ... most comprehensive line of accessories for the mobile lifestyle, ... to charge, sync, protect, and manage multiple iPad devices ... design award and the 2012 Good Design award, MultiCharger-X ... utilize the iPad, wherever it is deployed. , ...
(Date:5/22/2013)... York (PRWEB) May 22, 2013 ... 3rd Annual Disruptive Innovations to Advance Clinical Trials conference ... Plaza Hotel in Boston, MA. , Disruptive thinkers ... Pharmaceuticals and more share bold approaches to reduce expensive ... , “Disruptive innovation needs to be big, or novel, ...
(Date:5/22/2013)... 22, 2013  Empire Genomics announced today it ... pending novel genomic biomarker from Cornell University for ... could help in diagnosing and determining treatment for ... Neuroendocrine prostate cancer (NEPC) is a lethal ... de novo, but more commonly arises after hormonal ...
(Date:5/22/2013)... NEW ORLEANS , May 22, 2013 ... of regenerative medicine, presented new data generated in collaboration ... (a leading health economics consultancy) demonstrating the significant healthcare ... and venous leg ulcers (VLU) place upon the US ... research, which reveal annual costs of up to $15 ...
Breaking Biology Technology:iLuv Now Shipping the All New MultiCharger-X 2iLuv Now Shipping the All New MultiCharger-X 3Disruptive Innovation Hits Clinical Trials, Dedicated Event Launches 2Empire Genomics Licenses Novel DNA Biomarker for Use in Diagnosing and Creating a Companion Diagnostic Test for Neuroendocrine Prostate Cancer 2Organogenesis Presents Findings from Groundbreaking Research Highlighting the Healthcare Resource and Economic Burden of Venous Leg Ulcers and Diabetic Foot Ulcers 2Organogenesis Presents Findings from Groundbreaking Research Highlighting the Healthcare Resource and Economic Burden of Venous Leg Ulcers and Diabetic Foot Ulcers 3Organogenesis Presents Findings from Groundbreaking Research Highlighting the Healthcare Resource and Economic Burden of Venous Leg Ulcers and Diabetic Foot Ulcers 4
... , , , , , , ... Medical Genetics, , University Hospital and Medical School of the Dutch-speaking Brussels ... Brussels, Belgium, , , , , , ... , Preimplantation diagnosis (PGD) is ...
... , , , Peter ... PhD , Peter Scheinert, PhD, Bernhard-Nocht-Institute for Tropical ... , former address: University of Kiel, Institute for General ... Barbara Behrens, PhD, and Dietmar Kahle, PhD, Eppendorf-Netheler-Hinz GmbH, , ...
... , , , , , ... , pattern of a cell is examined in order to ... such as viral infections or medical treatment. , To ... to cDNA. If all isolated mRNAs of a cell are converted ...
Cached Biology Technology:The use of the Mastercycler gradient for single-cell PCR and preimplantation , diagnosis 2The use of the Mastercycler gradient for single-cell PCR and preimplantation , diagnosis 3The use of the Mastercycler gradient for single-cell PCR and preimplantation , diagnosis 4The use of the Mastercycler gradient for single-cell PCR and preimplantation , diagnosis 5Optimizing DNA Amplification Protocols using the Eppendorf Mastercycler 2Optimizing DNA Amplification Protocols using the Eppendorf Mastercycler 3Optimizing DNA Amplification Protocols using the Eppendorf Mastercycler 4Optimizing DNA Amplification Protocols using the Eppendorf Mastercycler 5Optimizing DNA Amplification Protocols using the Eppendorf Mastercycler 6Optimizing DNA Amplification Protocols using the Eppendorf Mastercycler 7Optimizing DNA Amplification Protocols using the Eppendorf Mastercycler 8Optimizing DNA Amplification Protocols using the Eppendorf Mastercycler 9Optimizing DNA Amplification Protocols using the Eppendorf Mastercycler 10Normalizing cDNA libraries using the EppendorfThermomixer 2Normalizing cDNA libraries using the EppendorfThermomixer 3Normalizing cDNA libraries using the EppendorfThermomixer 4
(Date:5/21/2013)... Mo. Cancers of all types become most deadly ... Once cancer has reached this stage, it becomes very ... tumors that can develop. Now, researchers at the University ... nanoparticles that target lymphoma tumor cells wherever they may ... of oncology in the MU College of Veterinary Medicine, ...
(Date:5/21/2013)... of Medicine will study gender differences in how the heart ... and how changes in fat metabolism play a role in ... the National Heart, Lung and Blood Institute. , When stressed, ... changes may play a major role in the development of ... E. Douglas Lewandowski, director of the UIC Center for Cardiovascular ...
(Date:5/21/2013)... decades, scientists have developed many devices that can reopen ... generally effective, each of these treatments has drawbacks, including ... from MIT analyzes the potential usefulness of a new ... drug-releasing stents, but may pose fewer risks. With this ... for only a brief period, during which it releases ...
Breaking Biology News(10 mins):MU researchers develop radioactive nanoparticles that target cancer cells 2Do men's and women's hearts burn fuel differently? 2Evaluating a new way to open clogged arteries 2Evaluating a new way to open clogged arteries 3
... what you might have heard, genetic sequencing alone is not ... Center have shown that functional tests are absolutely necessary to ... as they relate to disease, using a suite of diseases ... many different traits. "Right now the paradigm is ...
... Mo. They pop up in farm fields across 22 ... production agriculture that farmers have ever seen. They are "superweeds" ... popular gylphosate, also known as RoundUp and they cost ... farmers to plow them out of the field before they ...
... Research is trying to determine whether Alzheimer,s disease ... a new study suggests those efforts could be improved ... nutrient status of elderly people at risk for dementia. ... dietary surveys, asks people to remember what they have ...
Cached Biology News:Genetic sequencing alone doesn't offer a true picture of human disease 2Genetic sequencing alone doesn't offer a true picture of human disease 3Dow AgriSciences, MU researcher develop a way to control 'superweed' 2Study of nutrition, Alzheimer's links hampered by research approach 2
Contained in EZ-Tn5™ Kits and are available separately for sequencing of an insertion site....
p-Raf-1 (Ser 338/Tyr 341)-R...
Mouse monoclonal [Flt-1/EWC] to VEGF Receptor 1 ( Abpromise for all tested applications). entrezGeneID: 2321 SwissProtID: P17948...
MMP-1/8 (H-300)...
Biology Products: